Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To describe outcomes 5 years after initiating treatment with bevacizumab or ranibizumab for neovascular age-related macular degeneration (AMD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ophthalmology

Title: Ophthalmology

ISSN (Electronic): 1549-4713

ISSN (Print): 0161-6420

Publication date (Electronic): Aug 2016

Volume: 123

Issue: 8

Affiliations

[1 ] Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: maguirem@mail.med.upenn.edu.

[2 ] Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

[3 ] Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.

[4 ] Department of Ophthalmology, Duke University, Durham, North Carolina.

[5 ] National Eye Institute, National Institutes of Health, Bethesda, Maryland.

[6 ] Department of Ophthalmology, University of Colorado, Denver, Colorado.

Article

Publisher Item ID: S0161-6420(16)30092-6 Mid ID: NIHMS776214

DOI: 10.1016/j.ophtha.2016.03.045

PMC ID: 4958614

PubMed ID: 27156698

SO-VID: 20fcb55a-5cc2-4d08-a5da-82071ed5a676

History

Data availability:

Comments

Comment on this article

scite_

Cited by 231

See all cited by

- Version 1